![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase 1 study is designed to evaluate the safety and tolerability of EMP-01 (3,4-methylenedioxymethamphetamine) in participants, as well as assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to participants.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: EMP-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022